Isogenica today announced the appointment of Dr David Mead as Director of Business Development effective immediately. Dr Mead was previously Business Development Director at Albumedix where he was instrumental in signing significant royalty-bearing drug and vaccine development deals based on the company’s albumin-based formulation and half-life extension technologies.
“We are delighted to welcome Dr Mead to Isogenica and look forward to benefiting from his global licensing and alliance management experience in biopharmaceutical R&D,” said Dr Emma Sceats, CEO of Isogenica. “Strengthening our team with this senior level appointment is part of our core strategy as we increase the scope of our activities to enable broader, deeper relationships with biopharmaceutical partners and as we accelerate development of novel therapeutic antibodies based on Isogenica’s fully synthetic LlamdA™ single domain and Alexandria™ antigen binding fragment libraries.”
“I am delighted to join Isogenica,” said David Mead. “It’s exciting to become a part of a growing company that has great technologies and a team capable of creating real value for pharma partners, shareholders and ultimately patients. It is inspiring to be a part of a team that is striving to take Isogenica to the next level.”-
Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process. Over the last four years Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”
Download the press release.
Mandeep Sehmi, Business Development
T: +44 1799 533 680